Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation

[at noodls] – Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints NEW YORK, Jan. 2, 2013 — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its investigational oral … more

View todays social media effects on SGYPU

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view